AL-Eitan, L.N.; Almomani, B.A.; Nassar, A.M.; Elsaqa, B.Z.; Saadeh, N.A.
Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 Polymorphisms on Glycemic Control and HbA1c Levels. J. Pers. Med. 2019, 9, 17.
https://doi.org/10.3390/jpm9010017
AMA Style
AL-Eitan LN, Almomani BA, Nassar AM, Elsaqa BZ, Saadeh NA.
Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 Polymorphisms on Glycemic Control and HbA1c Levels. Journal of Personalized Medicine. 2019; 9(1):17.
https://doi.org/10.3390/jpm9010017
Chicago/Turabian Style
AL-Eitan, Laith N., Basima A. Almomani, Ahmad M. Nassar, Barakat Z. Elsaqa, and Nesreen A. Saadeh.
2019. "Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 Polymorphisms on Glycemic Control and HbA1c Levels" Journal of Personalized Medicine 9, no. 1: 17.
https://doi.org/10.3390/jpm9010017
APA Style
AL-Eitan, L. N., Almomani, B. A., Nassar, A. M., Elsaqa, B. Z., & Saadeh, N. A.
(2019). Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 Polymorphisms on Glycemic Control and HbA1c Levels. Journal of Personalized Medicine, 9(1), 17.
https://doi.org/10.3390/jpm9010017